Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

REDWOOD CITY, Calif. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta , chief executive officer of Menlo Therapeutics ,

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses a significant unmet medical need for

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

- Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Pruritus of Unknown Origin Expected January/February 2020 - REDWOOD CITY, Calif. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc.